Effects of selective serotonin reuptake inhibitors on the pharmacokinetics of proton pump inhibitors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4172/NEUROPSYCHIATRY.1000227
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• an update on

  2014cited by this paper
• Psychotropic Drug–Drug Interactions Involving P-Glycoprotein

  2012cited by this paper
• Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers

  2012cited by this paper
• Biological perspectives psychiatric drug-drug interactions: a review.

  2010influential reference
• Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

  2010cited by this paper
• P-glycoprotein related drug interactions: clinical importance and a consideration of disease states

  2010cited by this paper
• Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.

  2009cited by this paper
• Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

  2009cited by this paper
• Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.

  2008cited by this paper
• Drug-Drug Interaction Primer: A Compendium of Case Vignettes for the Practicing Clinician

  2007cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

  2006cited by this paper
• Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.

  2006cited by this paper
• Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

  2006cited by this paper
• Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics

  2005cited by this paper
• Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

  2005influential reference
• Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder

  2005cited by this paper
• Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction

  2004cited by this paper
• Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

  2004influential reference
• Identification of P‐glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates

  2004cited by this paper
• Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes

  2004influential reference
• A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine

  2004cited by this paper
• Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression

  2004cited by this paper
• Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

  2004cited by this paper
• Inhibition of P-Glycoprotein by Newer Antidepressants

  2003cited by this paper
• Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.

  2003cited by this paper
• Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

  2003cited by this paper
• Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

  2002cited by this paper
• Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

  2002cited by this paper
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

  2002cited by this paper
• Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH

  2001cited by this paper
• Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

  2001cited by this paper
• Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

  2001cited by this paper
• Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

  2001cited by this paper
• Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

  2001cited by this paper
• Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole

  1999cited by this paper
• Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

  1999cited by this paper
• Review article: the pharmacology of rabeprazole

  1999cited by this paper
• Effect of clarithromycin on renal excretion of digoxin: Interaction with P‐glycoprotein

  1998cited by this paper
• Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population

  1996cited by this paper
• Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.

  1996cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996cited by this paper
• Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status

  1995cited by this paper
• Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.

  1995cited by this paper
• Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects

  1993cited by this paper

• Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.

  2025cites this paper
• Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects

  2021cites this paper
• DDDT_A_309763 2375..2384

  2021cites this paper